Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817212) titled 'ESR1Real World Assessment Prevalence Study' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: Institut fuer Frauengesundheit
Condition:
HR+/HER2- aBC Undergoing 1L Treatment With CDK4/6i (Palbociclib, Abemaciclib or Ribociclib) and AI (Anastrozole or Letrozole)
Intervention:
Diagnostic Test: ESR1 testing
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: October 1, 2026
Target Sample Size: 1550
Countries of Recruitment:
Germany
To know more, v...